• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rheumatology (Oxford) . Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: A French study and lit

tetano

Editor, Senior Moderator
Rheumatology (Oxford)


. 2021 Jan 25;keab026.
doi: 10.1093/rheumatology/keab026. Online ahead of print.
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: A French study and literature review


Bilade Cherqaoui[SUP] 1 2 3 [/SUP], Isabelle Kon?-Paut[SUP] 1 2 4 [/SUP], H?l?ne Yager[SUP] 1 [/SUP], Fleur Le Bourgeois[SUP] 5 [/SUP], Maryam Piram[SUP] 2 4 6 [/SUP]



Affiliations

Abstract

Objective: To better define the clinical distinctions between the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related paediatric inflammatory multi-system syndrome (PIMS) and Kawasaki disease (kDa).
Methods: We compared three groups of patients: group 1, cases from our national historic kDa database (kDa-HIS); group 2, patients with kDa admitted to an intensive care unit (kDa-ICU) from both our original cohort and the literature; and group 3, patients with PIMS from the literature.
Results: kDa-HIS included 425 patients (male to female ratio 1.3, mean age 2.8 ? 2.4 years), kDa-ICU 176 (male to female ratio 1.3, mean age 3.5 ? 3.1 years), and PIMS 404 (male to female ratio 1.4, mean age 8.8 ? 3.7 years). As compared with kDa-HIS patients, kDa-ICU and PIMS patients had a higher proportion of cardiac failure and digestive and neurological signs. They also had lower frequency of typical mucocutaneous signs, lower platelet count, higher C-reactive protein level, and lower sodium level. As compared with kDa-HIS and kDa-ICU patients, PIMS patients were older and more frequently had myocarditis. They had fewer coronary abnormalities and lower sodium level. Unresponsiveness to intravenous immunoglobulins was more frequent in kDa-ICU than kDa-HIS and PIMS patients.
Conclusion: On clinical grounds, regular kDa, kDa-ICU and PIMS might belong to a common spectrum of non-specific pathogen-triggered hyperinflammatory states. The causes of increasing inflammation severity within the three entities and the different effects on the heart remain to be determined.

Keywords: COVID-19; Intensive Care Unit; Intravenous Immunoglobulins; Kawasaki disease; PIMS/MIS-C; SARS-CoV-2–related inflammatory multisystem syndrome; Shock syndrome; Systemic vasculitis.
 
Back
Top Bottom